Recludix Pharma Announces Strategic Collaboration With Sanofi For Oral STAT6 Inhibitor In Multiple Immunological And Inflammatory Indications; Recludix To Receive $125M In Near-term Payments And Potentially More Than $1.2B In Milestones
Portfolio Pulse from Benzinga Newsdesk
Recludix Pharma has announced a strategic collaboration with Sanofi for the development of an oral STAT6 inhibitor for multiple immunological and inflammatory indications. Recludix will receive $125M in near-term payments and potentially more than $1.2B in milestones.
July 20, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sanofi's strategic collaboration with Recludix Pharma for the development of an oral STAT6 inhibitor could potentially lead to new revenue streams. However, the company will have to make significant near-term payments and potentially more in milestones.
The partnership with Recludix Pharma could potentially open new revenue streams for Sanofi in the future. However, the significant near-term payments and potential milestone payments could impact the company's short-term financials. The overall impact on the stock is neutral as the potential benefits and costs are balanced.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100